Search research articles
Contact Us
Filters
Showing results (121-130 of 134) with videos related to
Page
of 14
Sort By:
Cancer Immunology Research
|
April 4, 2019
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Laura Evgin, Amanda L Huff, Timothy Kottke, et al.
Nature Communications
|
February 9, 2020
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy
Christopher B Driscoll, Matthew R Schuelke, Timothy Kottke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment
Magnus T Dillon, Katharina F Bergerhoff, Malin Pedersen, et al.
Journal for Immunotherapy of Cancer
|
March 26, 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
Galabina Bozhanova, Jehanne Hassan, Lizzie Appleton, et al.
Cancers
|
August 7, 2021
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma
Saira Khalique, Sarah Nash, David Mansfield, et al.
Nature Communications
|
March 27, 2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
Timothy Kottke, Jason Tonne, Laura Evgin, et al.
Nature Communications
|
July 8, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models
Joan Kyula-Currie, Victoria Roulstone, James Wright, et al.
Journal for Immunotherapy of Cancer
|
April 16, 2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
Reyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, et al.
Nature Communications
|
July 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
Victoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Nature Communications
|
May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
Victoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 134) with videos related to
Sort By:
Page
of 14
Cancer Immunology Research
|
April 4, 2019
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Laura Evgin, Amanda L Huff, Timothy Kottke, et al.
Nature Communications
|
February 9, 2020
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy
Christopher B Driscoll, Matthew R Schuelke, Timothy Kottke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment
Magnus T Dillon, Katharina F Bergerhoff, Malin Pedersen, et al.
Journal for Immunotherapy of Cancer
|
March 26, 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
Galabina Bozhanova, Jehanne Hassan, Lizzie Appleton, et al.
Cancers
|
August 7, 2021
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma
Saira Khalique, Sarah Nash, David Mansfield, et al.
Nature Communications
|
March 27, 2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
Timothy Kottke, Jason Tonne, Laura Evgin, et al.
Nature Communications
|
July 8, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models
Joan Kyula-Currie, Victoria Roulstone, James Wright, et al.
Journal for Immunotherapy of Cancer
|
April 16, 2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
Reyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, et al.
Nature Communications
|
July 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
Victoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Nature Communications
|
May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
Victoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Page
of 14